The global glycomics/glycobiology market size was estimated at USD 727.7 million in 2017. It is anticipated to expand at a 14.4% CAGR over the forecast period. Technological advancements are expected to drive the market. Rising investments in research by government and development of novel drugs by pharmaceutical and biotechnology companies are other major contributing factors. In addition, rising focus on glycomics and proteomics research studies is also anticipated to propel market expansion in near future.
Huge investments from governments and organizations have enabled academic researchers to develop new glycomics and glycobiology tools. This factor is anticipated to propel the field of glycoscience is at an impressive pace. This is a high-impact rendering driver for the market. As per many researchers, glycans are essential in biological processes. Glycan analysis helps in understanding biological more comprehensively, without specializing in glycobiology. This factors is anticipated to provide with a wide set of potential applications of glycan analysis.
In glycoproteomics, there is a need for advanced analytical methods for studying pathogen and human glycobiology in disease and health. Hence, there has been an increase in biomedical and proteomics research, leading to high growth of the market. Technological advancements have also contributed to the high demand for glycomics instruments. Procedures such as protein characterizations are evolving into advanced technologies such as High Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), and Capillary Electrophoresis (CE) in chemical and biochemical research. These advanced techniques provide rapid and high-sensitivity results.
Pharmaceutical and biotechnology companies are growing with increasing R&D activities, which include glycomics research. For instance, Thermo Fisher Scientific invested around USD 888 million in R&D in 2017. Agilent Technologies spent USD 339 million on R&D in 2017. Moreover, small pharmaceutical companies are controlling expenditure for operating activities, so that they can spend more on research and development. This factor is anticipated to accelerate glycomics/glycobiology in the years to come.
In 2017, instruments held the largest market share owing to frequent usage in drug discovery and diagnostic testing. In addition, repetitive purchase of reagents and kits is another major factor expected to boost segment growth. Enzymes are estimated to account for a considerable market share in near future due to rising research in cancer therapeutics and diagnosis.
Glycomics uses various research approaches to quantify or define glycome of a tissue, cell, or organism. Alteration such as localization or in the activity of enzymes involved in glycan biosynthesis ultimately results in changing of the final glycan structure. Therefore, apart from genetic markups of individuals, glycans can be analyzed to assess environmentally induced changes. This study can be used in disease diagnosis and drug discovery. This is one of the major factors propelling segment growth.
A large number of research studies have been conducted to commercialize glycoside inhibitors that are known to alter N-linked glycans of cancer cells and viruses. Therapeutic use of these enzymes include direct antiviral, antibacterial, and anti-cancer activities. They aid in treatment of diseases caused by deficiencies such as Tay-Sachs disease and Gaucher disease, and most importantly, diabetes. Thus, among enzymes, glycosidases held the largest market share in terms of revenue. The segment is anticipated to witness a CAGR of 15.8% during the forecast years.
Various research studies indicate that epigenetic regulation of glycans in cancer cells results in formation of new glycan structures. These structures are one of the mechanisms used by cancerous cells to evade immune response in a host. Scientists have designed genetic engineered cell models to understand functions of specific glycan cancer epitopes. These factors are therefore anticipated to propel growth of glycomics/glycobiology market during the forecast period.
On the basis of application, drug discovery and development accounted for the largest market share in 2017. This is primarily owing to increasing R&D and rising government funding for research related to glycomics and proteomics. The other applications segment is anticipated to showcase highest growth over the forecast period due to rising clinical trials and R&D expenses incurred by key players for extensive research.
With high R&D investments by pharmaceutical companies, demand for drug discovery and development of application in glycomics is increasing. For instance, R&D expenditure of Merck accounted for USD 2.4 billion in 2017. Research in glycome informatics, which helps in identification and analysis of drug targets and biomarkers, is increasing due to wide application of glycan structure analysis in bioinformatics.
Glycomics involves study of functions and structures of glycans in biological systems. Thus, it can be used in personalized medicines for early detection of diseases to select suitable line of treatment. Combining glycomics and genomics help in diagnosis of congenital disorders of glycosylation including CCDC115-CDG, ATP6AP1-CDG, PGM1-CDG, TMEM199-CDG, and MAN1B1-CDG.
Other application areas of glycomics/glycobiology are oncological, immunological, lysosomal storage, and other genetic diseases and disorders. Increasing number of clinical trials associated with glycomics and rising R&D investments by key players have led to lucrative growth of this segment. Hence, this segment is expected to expand at the highest CAGR of 15.9% over the forecast period.
On the basis of end use, academic and research institutes accounted for the largest revenue share in 2017 due to increasing R&D investments. High government funding for R&D is further boosting the revenue share of this segment. Collaborations between major organizations and research institutes are also one of the major demand drivers.
The pharmaceutical and biotechnology companies segment is anticipated to exhibit the highest CAGR of 15.6% during the forecast period owing to increasing R&D investments in drug discovery and development and in other glycobiology based studies. The escalating growth seen in academic and research institutes can be attributed to extensive adoption of glycan structure data analysis by research centers.
Increasing preference for glycomics for training and educational purposes is also a factor contributing to the substantial expansion of this segment. In addition, a wide range of applications in drug discovery and development, biomedical research, cell biology, immunology, and biochemistry is also expected to fuel market growth in near future.
North America region accounted for the largest market share in 2017 due to the presence of key pharmaceutical and biopharmaceutical companies including Merck KGaA, Agilent Technologies, Danaher, and Thermo Fisher Scientific. Presence of a well-developed healthcare infrastructure and accessibility to advanced products have fueled growth of the regional market. Moreover, huge government funding for R&D activities is also one of the significant factors driving regional growth.
Asia Pacific is expected to expand at the second highest CAGR during the forecast period owing to untapped market opportunities. Evolving pharmaceutical and biopharmaceutical industries have resulted in immense growth of glycomics in the region. In addition, heavy investments by Contract Research Organizations (CROs) for the development and production of drugs and biologics are expected to fuel growth of the Asia Pacific market.
Glycoscience with its significance in modern biotechnology and also its ability to access new and innovative technologies is anticipated to offer bio-based industries in Europe with competitive advantage at a global level. Developments have led to introduction of the European Glycoscience Network (EGSF) to address cross-disciplinary integrated interactions with global glycoscience networks established in U.S.
Latin America is anticipated to witness steady growth owing to rapidly developing economies, presence of leading pharmaceutical companies, and evolving healthcare infrastructure. Brazil is expected to expand at a lucrative CAGR during the forecast period owing to increasing life science-related research and developing healthcare infrastructure.
Market participants include both large, well-established public companies as well as private firms. These include Thermo Fisher Scientific, Inc.; Merck KGaA; Agilent Technologies;Bruker; New England Biolabs; Danaher; Shimadzu Corporation; Takara Bio, Inc.; and ProZyme. Majority of these companies have an extensive product portfolio coupled with strong regional presence.
Existence of a broad product portfolio and new product development are some of the major factors driving growth of companies. New product launches, mergers and acquisitions, partnerships, and collaborations are the key strategies adopted by leading companies for sustainable sector growth. For instance, in February 2018, Merck KGaA announced investment of 40 million Euros to enhance distribution and manufacturing services in the Asian region.
In another instance, in July 2018, Agilent Technologies announced the completion of acquisition of ULTRA Scientific Assets, a company engaged in distribution of certified chemical materials and standards. This acquisition is aimed to provide the company with life sciences solutions, creating a wider consumer base.
Glycomics is a relatively novel technique and research is being conducted on its innovative applications. Therefore, major market players are collaborating with academic institutes for development of newer techniques. For instance, collaboration brought about by Agilent Technologies with the University of Southern California to facilitate researchers in the field of diagnostics, new drug development, and medical devices.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2018 - 2025
Revenue in USD Million & CAGR from 2018 to 2025
North America, Europe, Asia Pacific, Latin America & MEA
U.S., Canada, Germany, U.K., Japan, India, China, Brazil, Mexico, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global glycomics/glycobiology market report on the basis of product, application, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Glycan Labeling Kits
Glycan Purification Kits
Glycan Release Kits
Application Outlook (Revenue, USD Million, 2014 - 2025)
Drug Discovery & Development
End-Use Outlook (Revenue, USD Million, 2014 - 2025)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2014 - 2025)
Middle East & Africa
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."